RCKT (Rocket Pharmaceuticals) Total Stockholders Equity : $463.23 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Total Stockholders Equity?

Rocket Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $463.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Rocket Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 was $4.35. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Rocket Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.06.

Rocket Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Rocket Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Total Stockholders Equity Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

503.52

454.72

489.69

492.57

463.23

Rocket Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															492.57	441.50	384.64	329.77	463.23

Rocket Pharmaceuticals (NAS:RCKT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Rocket Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(463.234	-	0)	/	106.454
	=	4.35

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Rocket Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.857	+	22.641)	/	463.234
	=	0.06

Rocket Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

9IP1:Germany 9IP1:Germany

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Executives

Gaurav Shah	director, officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel	officer: Chief Operating Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Jonathan David Schwartz	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Martin Wilson	officer: General Counsel	C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
John Militello	officer: See Remarks	C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Mark Andrew White	officer: Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
David P Southwell	director, officer: See Remarks	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Gotham Makker	director	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carlos Garcia-parada	officer: Chief Financial Officer	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork	director	C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam	officer: SVP - Finance & PFO	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Naveen Yalamanchi	director	412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder	officer: See Remarks	430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016